Spyre Therapeutics, Inc.
SYRE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $45 | $0 | $0 | $0 |
| Gross Profit | -$45 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $45 | $40 | $42 | $50 |
| G&A Expenses | $12 | $12 | $12 | $11 |
| SG&A Expenses | $12 | $12 | $12 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$45 | -$10 | $0 | $0 |
| Operating Expenses | $12 | $42 | $54 | $61 |
| Operating Income | -$57 | -$42 | -$54 | -$61 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $46 | $5 | $9 | $5 |
| Pre-Tax Income | -$11 | -$37 | -$45 | -$56 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$11 | -$37 | -$45 | -$56 |
| % Margin | – | – | – | – |
| EPS | -0.15 | -0.6 | -0.13 | -0.15 |
| % Growth | 75% | -361.5% | 13.3% | – |
| EPS Diluted | -0.15 | -0.6 | -0.13 | -0.15 |
| Weighted Avg Shares Out | 75 | 61 | 60 | 47 |
| Weighted Avg Shares Out Dil | 60 | 61 | 60 | 47 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $6 | $6 | $6 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$52 | -$54 | -$61 |
| % Margin | – | – | – | – |